Alphatec (NASDAQ:ATEC) Reaches New 1-Year High - What's Next?

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $12.85 and last traded at $12.72, with a volume of 985887 shares changing hands. The stock had previously closed at $12.67.

Wall Street Analysts Forecast Growth

ATEC has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a report on Friday, May 2nd. Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Trading Up 1.7%

The business has a fifty day simple moving average of $10.73 and a 200-day simple moving average of $10.35. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -10.13 and a beta of 1.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. During the same period in the previous year, the company earned ($0.34) EPS. Alphatec's revenue for the quarter was up 22.2% on a year-over-year basis. As a group, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alphatec news, COO Scott Lish sold 12,000 shares of the company's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the sale, the chief operating officer now owns 826,251 shares in the company, valued at approximately $10,014,162.12. The trade was a 1.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Patrick Miles sold 12,691 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the completion of the sale, the chief executive officer now owns 5,857,603 shares in the company, valued at $62,324,895.92. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 126,945 shares of company stock valued at $1,416,352 in the last 90 days. Corporate insiders own 20.90% of the company's stock.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in shares of Alphatec in the 4th quarter valued at about $29,000. Comerica Bank grew its position in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after purchasing an additional 4,234 shares in the last quarter. Quarry LP boosted its position in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC bought a new stake in shares of Alphatec during the 4th quarter valued at about $50,000. Institutional investors own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.